Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-10T15:36:12.776Z Has data issue: false hasContentIssue false

Proteomics as a tool for the modelling of biological processes and biomarker development in nutrition research

Published online by Cambridge University Press:  01 June 2008

Baukje de Roos*
Affiliation:
Division of Vascular Health, Rowett Research Institute, Greenburn Road, Bucksburn, AberdeenAB21 9SB, United Kingdom
Harry J. McArdle
Affiliation:
Division of Vascular Health, Rowett Research Institute, Greenburn Road, Bucksburn, AberdeenAB21 9SB, United Kingdom
*
*Corresponding author: Dr Baukje de Roos, fax +44 (0)1224 716629, email b.deroos@rowett.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Nutrition research has slowly started to adopt the proteomics techniques to measure changes in the protein complement of a biological system. This enables modelling of biological processes in response to dietary interventions, as well as the elucidation of novel biomarkers for health or disease that are sensitive to such interventions. There are limited studies on the effect of micronutrients on the proteome, so this review concentrates rather more on dietary intervention studies that have used proteomics (mainly classical 2D gel electrophoresis combined with mass spectrometry) to elucidate changes in pathways that relate to glucose and fatty acid metabolism, oxidative stress, anti-oxidant defence mechanisms and redox status. The ability to measure regulation of more low abundant proteins, such as those involved in inflammatory pathways, as well as the evaluation and validation of newly discovered candidate biomarkers in human biofluids, may depend on the introduction of more quantitative and sensitive methods like multiple reaction monitoring (MRM) and multiplexed immunoassays in nutrition research.

Type
Full Papers
Copyright
Copyright © The Authors 2008

Epidemiological studies show strong associations between diet and the incidence and severity of disease(Reference Hu and Willett14). However, the identification of the bioactive components from diets and foodstuffs and defining their mode of action is challenging. Diets are complex, consisting of many separate food items, and each food item itself is a complex mix of bioactive components(Reference Brown and van der5). Their interactions with physiological systems, therefore, are very difficult to deduce using traditional experimental methods. The global nature of nutrigenomics technology is a real advantage for elucidating the complex physiological effects of food components, nutrients, or a specific diet, which are often mediated through multiple biochemical and molecular mechanisms. Furthermore, knowledge about the actions of foods and nutrients on all possible physiological outcomes related to, for example, chronic disease development, is essential to identify dietary strategies that will promote health and delay the onset of chronic diseases.

The potential value of proteomics for nutritional sciences has been recognised for some years and many authors have written excellent reviews (see, for example(Reference Kim, Page and Barnes6Reference Milner10)) promulgating its use in nutrition. However, the total number of reviews published up to 2007 actually exceeds the number of research papers on proteomics! (Fig. 1). When searching Pubmed, using the search terms (proteomic*) and (nutrition* or diet* or food), and eliminating all proteomics-related publications that i) were not published in English; ii) were not dealing with an in vivo or in vitro dietary intervention, or iii) were based on plant/food/crop proteomics only, we found 88 reviews and only 73 research papers. Thus, whilst proteomics is presented as an emerging and promising tool that enables the elucidation of mechanisms of action as well as development of relevant biomarkers of health or disease, the actual use of this technique in dietary intervention trials is still rather limited. In relation to micronutrient metabolism, there are only a few papers examining either the proteomic consequences of dietary treatment or the potential for proteomics to be used as a biomarker for status. In this review, therefore, we have also included other dietary treatments, that can be used as examples of the method and hopefully provide inspiration to others to adopt the techniques in their micronutrient research.

Fig. 1 Reviews and research papers relating to proteomics, nutrition, diet and food published from 2000–2007.

Proteomics as a tool to elucidate mechanisms of action

Proteomics has the advantage over cDNA micro-arrays in that it measures the functional product (protein) of gene expression, and allows the identification of modifications that may relate to the activation or inactivation of proteins by dietary interventions. Such proteins may not only play a major physiological role in target organs, but could also reflect changes in mechanisms initiated by dietary intervention when circulating in the blood.

Classical two-dimensional (2D) gel electrophoresis, coupled with spot analysis by mass spectrometry, is still the most widely used technical approach in proteomics to identify changes in individual proteins of tissues, cells and biofluids upon nutritional intervention(Reference Fuchs, Winkelmann, Johnson, Mariman, Wenzel and Daniel7, Reference Kim, Page and Barnes6). While this method is one of the most labour-intensive of the several types of 2D separation methods available, it actually yields a physical separation of intact polypeptides from each other, providing information about molecular weight and iso-electric point, parameters that can be used to narrow down the identification of the protein(Reference Barnes and Kim11). However, the dynamic range of protein concentrations spans six orders of magnitude in a cell, and even 10 in the human body (for example in plasma). Proteins involved in inflammatory pathways, like cytokines, are secreted and circulate in the body at a concentration nine orders of magnitude less than albumin(Reference Kenyon, DeMarini, Fuchs, Galas, Kirsch, Leyh, Moos, Petsko, Ringe, Rubin and Sheahan12). It is currently difficult to visualise and detect differential regulation of low abundant, very hydrophobic, acidic or basic proteins(Reference Gygi, Corthals, Zhang, Rochon and Aebersold13). Therefore, 2D gel electrophoresis may not always represent the most sensitive tool to reveal effects of nutritional interventions on inflammatory pathways. On the other hand, 2D gel electrophoresis and mass spectrometry has established itself as a valuable tool in elucidating changes in pathways that relate to glucose and fatty acid metabolism as well as pathways relating to oxidative stress, anti-oxidant defence mechanisms and redox status(Reference de Roos, Duivenvoorden, Rucklidge, Reid, Ross, Lamers, Voshol, Havekes and Teusink14Reference de Roos, Duthie, Polley, Mulholland, Bouwman, Heim, Rucklidge, Johnson, Mariman, Daniel and Elliott16).

Studies in our laboratory have demonstrated that two structurally almost identical dietary conjugated linoleic acid (CLA) isomers had divergent mechanistic effects on atherosclerosis development and insulin resistance in Apoe − / −  mice. Consumption of trans10, cis12 CLA, a fatty acid present in supplements that are currently freely available, was pro-atherogenic and induced pathways involved in the development of insulin resistance, as evidenced by simultaneous changes in various enzymes involved in gluconeogenesis, glycolysis and ketogenesis(Reference de Roos, Rucklidge, Reid, Ross, Duncan, Navarro, Arbones-Mainar, Guzman-Garcia, Osada, Browne, Loscher and Roche17). Consumption of cis9, trans11 isomer of CLA, on the other hand, was anti-atherogenic and specifically induced heat shock protein (HSP) 70 kD protein levels(Reference de Roos, Rucklidge, Reid, Ross, Duncan, Navarro, Arbones-Mainar, Guzman-Garcia, Osada, Browne, Loscher and Roche17). Although one may consider this to be an indication of increased oxidative stress, we have postulated that up-regulation of HSP 70 kD protein upon exposure to a relatively mild stress stimulus (like cis9, trans11 CLA) could protect against exposure to more severe stress later, possibly including anti-inflammatory pathways (mediated through NF-κB)(Reference Shimizu, Tamamori-Adachi, Arai, Tabuchi, Tanaka and Sunamori18). Indeed, increased levels of human serum HSP 70 have been associated with a low coronary artery disease risk, independent of traditional risk factors(Reference Zhu, Quyyumi, Wu, Csako, Rott, Zalles-Ganley, Ogunmakinwa, Halcox and Epstein19).

Using proteomics, we were also able to show that the consumption of dietary fish oil and trans10, cis12 CLA induced differential expression of long chain acyl-CoA thioester hydrolase protein as an indicator of β-oxidation of fatty acids in the liver, and the consumption of dietary fish oil, olive oil and trans10, cis12 CLA induced differential expression of adipophilin protein as an indicator of selective hepatic lipid accumulation and triglyceride secretion(Reference de Roos, Duivenvoorden, Rucklidge, Reid, Ross, Lamers, Voshol, Havekes and Teusink14, Reference de Roos, Rucklidge, Reid, Ross, Duncan, Navarro, Arbones-Mainar, Guzman-Garcia, Osada, Browne, Loscher and Roche17).

In a recent study we applied a systems biology approach to gain a better understanding of the mechanisms by which the fatty acids of olive oil, or its minor antioxidant constituents, may affect hepatic metabolic pathways, oxidative stress and eventually atherogenesis. Extra virgin olive oil reduced atherosclerotic plaque size after 10 weeks of intervention in apolipoprotein E knockout (Apoe − / − ) mice but also induced the accumulation of triglycerides in the liver, resulting in an increased hepatic fat content. These results imply that olive oils can, on the one hand, reduce the risk of atherosclerotic plaque formation, but can also increase the risk of hepatic steatosis. A systems biology approach appeared to be crucial for unravelling the complex interactions. We found a significant up-regulation of a large array of antioxidant enzymes upon consumption of extra virgin olive oils that may diminish oxidative stress instigated by hepatic steatosis and in addition, may slow down the development of atherosclerosis. Therefore, compounds in extra virgin olive oils (such as the polyphenols) may well be able to delay the onset of atherosclerotic lesions by combatting oxidative stress. Indeed, the accumulation of triglycerides may not pose a major challenge to the liver, and represent a relatively safe way to store triglycerides, as long as the antioxidant capacity is adequate to prevent lipotoxicity(Reference Arbones-Mainar, Ross, Rucklidge, Reid, Duncan, Arthur, Horgan, Navarro, Carnicer, Arnal, Osada and Roos15).

A combination of transcriptomics and proteomics was used to determine mechanisms of (supra-physiological concentrations of) dietary quercetin in the healthy distal colon of inbred F344 rats, and revealed that quercetin changed the cellular energy metabolism from glycolysis in the cytoplasm towards fatty acid degradation in the mitochondria. Cancer cells generally exhibit increased glycolysis and mitochondrial dysfunction, and in human colon tumours an increase in glycolysis combined with decreased fatty acid degradation as an energy source has been observed previously. Therefore, the quercetin-mediated glycolysis-to-fatty acid degradation shift in energy pathways could represent an additional underlying mechanism involved in quercetin's potency to inhibit induced colorectal carcinogenesis(Reference Dihal, van der, Hendriksen, Charif, Dekker, Ijsselstijn, de Boer, Alink, Burgers, Rietjens, Woutersen and Stierum20).

A combination of transcriptomics and proteomics was also applied to explain the mechanisms underlying changes in hepatic lipid metabolism during zinc deficiency(Reference Tom, Doring, Fuchs, Roth and Daniel21). Zinc is involved in many aspects of normal physiology, including intermediary metabolism, hormone secretion pathways, and immune defence. Deficiency has severe consequences, but the mechanisms involved are largely unknown. The results of this study provided evidence for major changes in the expression of gene groups functionally linked to hepatic lipogenesis and lipolysis, with an inverse regulation that fostered the accumulation of triglycerides in liver, changing the hepatic fatty acid pattern, and reducing fatty acid oxidation. The experimental findings provided support for an unbalanced gene transcription control via peroxisome proliferator activated receptor alpha (PPARα), thyroid hormone, and sterol regulatory element binding protein (SREBP)-dependent pathways, which may explain most of the apparently pleiotropic effects of zinc deficiency on hepatic fat metabolism(Reference Tom, Doring, Fuchs, Roth and Daniel21).

Proteomics was used as a tool to explore biochemical alterations in the adult brain after developmental vitamin D deficiency. For this, vitamin D-deficient female rats were mated with vitamin D normal males. Pregnant females were kept vitamin D-deficient until birth whereupon they were returned to a control diet. At week 10, protein expression in the progeny's prefrontal cortex and hippocampus was compared with control. Developmental vitamin D deficiency led to long-lasting alterations in expression of brain proteins involved in mitochondrial, cytoskeletal and neuronal function. Specifically, 36 proteins were identified which were involved in, for example, oxidative phosphorylation, redox balance, cytoskeleton maintenance, calcium homeostasis, chaperoning and neurotransmission. An in silico survey of vitamin D target genes identified a putative vitamin D responsive element in the promoter region of 6 of these 36 proteins. Interestingly, many of the proteins found to be dysregulated in this study have also been identified in post-mortem and genetic studies in patients with schizophrenia or multiple sclerosis, the most prominent similarity being the dysregulation of mitochondrial proteins(Reference Almeras, Eyles, Benech, Laffite, Villard, Patatian, Boucraut, Mackay-Sim, McGrath and Feron22).

A rat model of oxidative stress was used to investigate the mechanism(s) whereby salicylic acid modulates potentially pro-cancerous activity in the colon using a proteomic approach. Supplementation of salicylic acid (1 mg/kg diet) resulted in a significant change in expression of 55 cytosolic proteins extracted from the distal colon milled in liquid nitrogen. The functions of these proteins related to protein folding, protein transport, redox balance, energy metabolism and cytoskeletal regulation. Partial least squares analysis was performed to identify associations between significantly altered proteins and biochemical indices of oxidative stress (plasma and colon thiobarbiturate reactive substances (TBARS)), prostaglandin levels and cytosolic glutathione peroxidase (cyGPx) activity data. Seven of the proteins were involved in the two major redox pathways of thioredoxin and glutathione, which implies that salicylic acid can regulate redox signalling via similar pathways to vitamin E, but may do this indirectly through modulation of interactive components of the redox signalling system(Reference Drew, Padidar, Horgan, Duthie, Russell, Reid, Duncan and Rucklidge23).

A last example of a proteomics approach that illustrates the technique's ability to measure oxidative stress and metabolic changes is given in a paper published by Opii and colleagues(Reference Opii, Joshi, Head, Milgram, Muggenburg, Klein, Pierce, Cotman and Butterfield24). These authors investigated the effect of a long-term treatment with an antioxidant-fortified diet for 2·8 years (containing vitamin E, l-carnitine, dl-alpha-lipoic acid, vitamin C, and spinach flakes, tomato pomace, grape pomace, carrot granules and citrus pulp) and/or a program of behavioural enrichment on oxidative damage in the parietal cortex. They used aged Beagles as a model for human aging as these dogs naturally develop cognitive deficits and accumulate brain pathology that is similar to aging humans. The combined treatment caused the greatest decrease in the oxidative stress biomarkers protein carbonyls, 3-nitrotyrosine (3-NT), and the lipid peroxidation product 4-hydroxynonenal (HNE). Using comparative proteomics they found that protein carbonyl levels of glutamate dehydrogenase [NAD (P)], glyceraldehyde-3-phosphate dehydrogenase (GAPDH), α-enolase, neurofilament triplet L protein, glutathione-S-transferase (GST) and fascin actin bundling protein were significantly decreased and that the protein levels of Cu/Zn superoxide dismutase (Cu/Zn SOD), fructose-bisphosphate aldolase C, creatine kinase, glutamate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase were increased in brain of the combined treatment group. The increased expression of a number of antioxidant proteins, in particular Cu/Zn SOD, correlated with improved cognitive function. These findings suggest that the anti-oxidant plus behavioural enrichment treatment decreases the levels of oxidative damage and improves the antioxidant reserve systems in the aging canine brain, and may contribute to improvements in learning and memory(Reference Opii, Joshi, Head, Milgram, Muggenburg, Klein, Pierce, Cotman and Butterfield24).

Proteomics as a tool for biomarker development

Dietary intervention causes changes in proteins that are secreted or otherwise released into the blood. An enormous asset of the proteomics platform is, therefore, the quantitative, non-invasive analysis of human body fluids to determine the consequences of such interventions. Plasma or serum, and circulating cells such as lymphocytes and platelets, can be relatively easily obtained from blood(Reference Fuchs, Winkelmann, Johnson, Mariman, Wenzel and Daniel7, Reference de Roos, Duthie, Polley, Mulholland, Bouwman, Heim, Rucklidge, Johnson, Mariman, Daniel and Elliott16) and proteomics technologies have the potential to deliver biomarkers for health, to reveal early indications of disease risk, assist in differentiating dietary responders from non-responders, and to discover beneficial food components(Reference Kussmann, Raymond and Affolter9). Currently the major problem with this approach seems to be reproducibility(Reference Astle, Ferguson, German, Harrigan, Kelleher, Kodadek, Parks, Roth, Singletary, Wenger and Mahady25). It is well known that high-dimensional biological technologies, such as proteomics, are liable to errors from both biological and non- biological variability. Some causes may include reagent and gel variability, technical variations, temperature and dye/stain incorporation. Biological variability may arise from factors such as circadian rhythm, sex, age, and smoking status, many of which may be unmeasured and, indeed, unquantifiable(Reference Kim, Page and Barnes6, Reference de Roos, Duthie, Polley, Mulholland, Bouwman, Heim, Rucklidge, Johnson, Mariman, Daniel and Elliott16). These sources of variation may easily obscure the biological changes under investigation, and this has led some to argue that proteomic profiling of blood is a relatively immature technology in need of further refinement(Reference Coombes, Morris, Hu, Edmonson and Baggerly26).

The extent of the inter-individual variability of the human proteome remains unclear but is an important factor to try and quantify(Reference Gerszten and Wang27). We are currently addressing this issue in a ‘proof-of-principle’ initiative funded by the European Nutrigenomics Organisation (NuGO) Network of Excellence. This project aims to determine biological variability in plasma, saliva, urine, platelet and peripheral blood mononuclear cell (PBMC) proteomics in healthy individuals during baseline and after a fasting challenge. In addition, we recently systematically assessed analytical variation in 2D gel electrophoresis of a depleted plasma, platelet and peripheral blood mononuclear cell protein homogenate within and between four laboratories.

We found that the within-laboratory coefficient of variation (CV) between gels (based on all visual spots on the 2D gel) ranged from 18–68 % in four different laboratories, whereas the between-laboratory CV (based on 30 pre-selected abundant protein spots) ranged between 22–34 %. This variation must be considered when designing human intervention studies that use proteomics tools to elucidate the (often subtle) effects of dietary compounds on potential novel biomarkers of health. Several steps in the proteomics procedure appeared particularly critical for and contributed to this variation. Amongst these were reproducible depletion of plasma of its most abundant proteins, contamination of circulating cells with other cells from blood, use of tricine to improve the running conditions of the 2D gel electrophoresis procedure, acquisition of high resolution images for comparative analysis, and the careful assessment of spot identifications obtained by matrix assisted laser desorption/ionization-time of flight (MALDI-TOF) or liquid chromatography/mass spectrometry/mass spectrometry (LC-MS/MS) analysis(Reference de Roos, Duthie, Polley, Mulholland, Bouwman, Heim, Rucklidge, Johnson, Mariman, Daniel and Elliott16).

Despite these problems, proteomics has a real potential for the development of biomarkers. In one of our recent trials we assessed the effects of daily fish oil for six weeks on the serum proteome using 2-DE. We found that serum levels of apolipoprotein A1, apolipoprotein L1, zinc-α-2-glycoprotein, haptoglobin precursor, α-1-antitrypsin precursor, anti-thrombin III-like protein, serum amyloid P component, and haemopexin were all significantly down-regulated (all P < 0·05) by fish oil compared with high oleic sunflower oil supplementation. In addition, the decrease in serum apolipoprotein A1 was associated with a significant shift towards the larger, more cholesterol-rich high density lipoprotein 2 (HDL2) particles. The alterations in serum proteins and HDL size imply that fish oil activates anti-inflammatory and lipid modulating mechanisms believed to impede the early-onset of coronary heart disease (CHD). These proteins are potential diagnostic biomarkers to assess the mechanisms whereby fish oils protect against CHD in humans(Reference de Roos, Geelen, Ross, Rucklidge, Reid, Duncan, Caslake, Horgan and Brouwer28).

A proteomics approach was also used to identify alterations in PBMC proteins of healthy males ingesting flaxseed for a week. PBMC's from the same study subjects were also exposed to physiological concentrations of enterolactone (a metabolite produced from dietary lignans by colonic microflora) ex vivo to assess whether similar effects on the proteome could be observed as those caused by dietary flaxseed. Intervention with flaxseed in healthy males resulted in enhanced plasma enterolactone levels in all volunteers, although both baseline levels and maximal plasma concentrations varied considerably between subjects. In addition, a fairly robust change in 16 PBMC proteins was observed upon consumption of flaxseed. Four out of these sixteen proteins were altered in a similar manner when blood mononuclear cells were exposed ex vivo to enterolactone: enhanced levels of peroxiredoxin, decreased levels of the long-chain fatty acid β-oxidation multi-enzyme complex proteins, and levels of glycoprotein IIIa/II(Reference Fuchs, Piller, Linseisen, Daniel and Wenzel29).

Proteomics of PBMC's was also used to identify biomarkers of response to a dietary supplementation with an isoflavone extract for 8 weeks in postmenopausal women. Twenty-nine proteins, including several involved in the anti-inflammatory response, showed significantly altered expression in the mononuclear blood cells following the soy-isoflavone intervention. Heat shock protein 70, a lymphocyte-specific protein phosphatase and proteins that promote increased fibrinolysis, such as α-enolase, were all found at increased intensities, whereas those that mediate adhesion, migration, and proliferation of vascular smooth muscle cells, such as galectin-1, showed decreased expression. As no overall anti-inflammatory activity of the soy intervention was observed when clinically relevant inflammation markers were measured in plasma, it was suggested that the PBMC proteome may represent a more sensitive approach to detect inhibition of inflammatory processes and that may also respond earlier than those plasma markers classically used(Reference Fuchs, Vafeiadou, Hall, Daniel, Williams, Schroot and Wenzel30).

Future developments

It is unlikely that a single protein, by itself, clearly defines a specific treatment effect distinguishing it from all other diseases or conditions(Reference Vasan31). Having several markers may allow a more definite diagnosis, better disease stratification and additional value. Some caution must be exercised, however. It has been suggested that a large number of correlated biomarkers (although underscoring the importance of a specific biological pathway) is substantially less informative and predictive than a small number of uncorrelated biomarkers(Reference Gerszten and Wang27). Furthermore, when considering the importance of specific biological pathways, it is important to note that the combination of proteomics data with physiological parameters, using the powerful statistical tool of correlation analysis, will provide clearer insights into the mechanisms by which dietary components regulate metabolic processes and ultimately change phenotypes(Reference Milner10, Reference de Roos, Duivenvoorden, Rucklidge, Reid, Ross, Lamers, Voshol, Havekes and Teusink14, Reference de Roos, Rucklidge, Reid, Ross, Duncan, Navarro, Arbones-Mainar, Guzman-Garcia, Osada, Browne, Loscher and Roche17).

To date, transcriptomics has been more readily embraced by the nutrition research community. However, as new and improved proteomics techniques emerge this may change(Reference Brown and van der5). So far, most applied proteomic methods have been based on 2D gel electrophoresis, which is undirected and semi-quantitative. While differences based on abundance may look obvious in a given 2D gel or MS spectrum, obtaining accurate measures over multiple samples analysed at different times is more difficult. Furthermore, high-abundance proteins will be identified many more times than low-abundance proteins. Other approaches are beginning to be developed which may help to solve these problems(Reference Drake and Ping32).

A recent advance is the introduction of difference gel electrophoresis (DIGE) technology, allowing for direct quantitative measurements between differentially labelled samples using cyanine fluorescent dyes prior to gel electrophoresis. When absolute protein variation between two or three samples is the primary target, this method is more reproducible and accurate and not limited by distortion from gel-to-gel variation(Reference Issaq and Veenstra33), but it is costly and automation is difficult(Reference Kussmann34). Shotgun proteomics (digestion of the protein mixture and multidimensional chromatographic separation of peptides followed by on-line mass spectrometric peptide detection and sequencing(Reference Kussmann and Affolter8)) can also be combined with stable isotope labelling to allow for the quantification of changes in protein expression levels of hundreds to thousands of proteins in a single experiment. The most commonly adopted approaches include isotope-coded affinity tags (ICAT)(Reference Smolka, Zhou, Purkayastha and Aebersold35) and isobaric tag relative absolute protein quantitation (iTRAC)(Reference Streckfus, Mayorga-Wark, Arreola, Edwards, Bigler and Dubinsky36) methods. However, quantification is based on relative changes in the levels of labelled peptides that may be common to a family of proteins, with differential regulation/ abundance, and therefore quantification experiments can lead to ambiguous or conflicting results(Reference Duncan and Hunsucker37).

Recently, triple quadrupole-derived technologies combined with a new generation linear ion trap have enabled quantitative analysis of (known) specific peptides (including those that are post-translationally modified) in complex biological mixtures such as human plasma and serum with very high sensitivity and selectivity in the multiple reaction monitoring (MRM) mode. The high selectivity results from monitoring one pair of precursor/fragment ions characteristic of a single peptide. In addition, two levels of mass selection in MRM experiments result in a substantial increase in sensitivity, because the first filter only transmits a small ion population, and thus minimises the overall chemical background. By adding calibrated, isotopically labelled reference peptides, precise quantitative information can be obtained(Reference Domon and Aebersold38). This approach represents a significantly faster and probably less expensive tool to quantitatively measure low abundance proteins in blood (present at low nanogram/milliliter concentrations) that can be highly ‘multiplexed,’ permitting the simultaneous measurement of multiple proteins. Furthermore, the within-run coefficients of variation are between 2–22 %, which is significantly lower than other proteomic approaches(Reference Anderson and Hunter39). Such an approach may provide better opportunities to observe subtle changes in for example inflammatory pathway-related protein markers upon dietary intervention. Alternatively, arrays of spotted antibodies have become available as a new tool for protein profiling. Many such arrays focus on plasma proteins such as cytokines and adipokines, which are protein classes of interest for nutrigenomics studies(Reference Nielsen and Geierstanger40). This technology will develop in the coming years, both in performance and in the number of proteins that can be analysed simultaneously(Reference Mariman41).

SELDI (surface enhanced laser desorption/ionisation time of flight mass spectroscopy) has had a mixed press in terms of value for high throughput proteomics. In theory, it should be an excellent system. It uses differentially chemically modified surfaces to bind proteins or peptides of interest. These surfaces include anion and cation exchangers, immobilised metal affinity surfaces, hydrophobic and antibody binding, among others. The proteins are eluted using lasers of different strengths and the peptides separated on a time of flight mass spectrometer. The spectra can be compared for differences between conditions. The system has been used extensively in pharmacological and health and disease comparisons(Reference Cieniewski-Bernard, Acosta, Dubois, Lamblin, Beseme, Chwastyniak, Amouyel, Bauters and Pinet42), but much less so in nutritional treatments(Reference Linke, Ross and Harrison43, Reference Roelofsen, Balgobind and Vonk44) (Miller, Gambling, Araya and McArdle, unpublished data). However, there are some problems, especially in translating the technology from the laboratory to the field or bedside. This is well reviewed by Reymond and Schlegel(Reference Reymond and Schlegel45). Many of these problems are shared by other proteomics technologies, since they relate to such things as storage of samples, variations between patients, subtle changes in disease state or progress, diurnal variation and age. However, the extra sensitivity of SELDI means that it is more liable to give false positives or negatives, so careful statistical analysis is essential.

Conclusion

Current proteomics approaches in nutrition research mainly include the use of protein separation, visualisation and identification by 2D gel electrophoresis combined with mass spectrometry. Despite the few number of studies that have been undertaken so far, and despite its limited ability to detect regulation of low abundant proteins, this approach has already provided valuable insights in the effects of several dietary interventions on (relatively abundant) proteins involved in the regulation of glucose and fatty acid metabolism, oxidative stress, and the redox system. The success of proteomics in nutrition research will depend on the introduction and adaptation of more quantitative and sensitive methods, which are currently already being validated and applied in the pharmaceutical industry. Such methods will enable the development of assays to evaluate and validate newly discovered candidate biomarkers in human biofluids.

Acknowledgements

The authors' work is funded by the Scottish Government Rural and Environment Research and Analysis Directorate (RERAD), the European Union (NuGO) and the International Copper Association.

References

1Hu, FB & Willett, WC (2002) Optimal diets for prevention of coronary heart disease. JAMA 288, 25692578.CrossRefGoogle ScholarPubMed
2Van Horn, L, McCoin, M, Kris-Etherton, PM, Burke, F, Carson, JA, Champagne, CM, Karmally, W & Sikand, G (2008) The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 108, 287331.CrossRefGoogle ScholarPubMed
3Riboli, E & Norat, T (2003) Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 78, 559S569S.CrossRefGoogle ScholarPubMed
4World cancer research Fund AIfCR (editors) (2007) Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington: World Cancer Research Fund.Google Scholar
5Brown, L & van der, OF (2007) Nutritional genomics: food industry applications from farm to fork. Br J Nutr 97, 10271035.CrossRefGoogle ScholarPubMed
6Kim, H, Page, GP & Barnes, S (2004) Proteomics and mass spectrometry in nutrition research. Nutrition 20, 155165.CrossRefGoogle ScholarPubMed
7Fuchs, D, Winkelmann, I, Johnson, IT, Mariman, E, Wenzel, U & Daniel, H (2005) Proteomics in nutrition research: principles, technologies and applications. Br J Nutr 94, 302314.CrossRefGoogle ScholarPubMed
8Kussmann, M & Affolter, M (2006) Proteomic methods in nutrition. Curr Opin Clin Nutr Metab Care 9, 575583.CrossRefGoogle ScholarPubMed
9Kussmann, M, Raymond, F & Affolter, M (2006) OMICS-driven biomarker discovery in nutrition and health. J Biotechnol 124, 758787.CrossRefGoogle ScholarPubMed
10Milner, JA (2007) Nutrition in the ‘omics’ era. Forum Nutr 60, 124.CrossRefGoogle ScholarPubMed
11Barnes, S & Kim, H (2004) Nutriproteomics: identifying the molecular targets of nutritive and non-nutritive components of the diet. J Biochem Mol Biol 37, 5974.Google ScholarPubMed
12Kenyon, GL, DeMarini, DM, Fuchs, E, Galas, DJ, Kirsch, JF, Leyh, TS, Moos, WH, Petsko, GA, Ringe, D, Rubin, GM & Sheahan, LC (2002) Defining the mandate of proteomics in the post-genomics era: workshop report. Mol Cell Proteomics 1, 763780.CrossRefGoogle ScholarPubMed
13Gygi, SP, Corthals, GL, Zhang, Y, Rochon, Y & Aebersold, R (2000) Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 97, 93909395.CrossRefGoogle ScholarPubMed
14de Roos, B, Duivenvoorden, I, Rucklidge, G, Reid, M, Ross, K, Lamers, RJ, Voshol, PJ, Havekes, LM & Teusink, B (2005) Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data. FASEB J 19, 813815.CrossRefGoogle ScholarPubMed
15Arbones-Mainar, JM, Ross, K, Rucklidge, GJ, Reid, M, Duncan, G, Arthur, JR, Horgan, GW, Navarro, MA, Carnicer, R, Arnal, C, Osada, J & Roos, BD (2007) Extra Virgin Olive Oils Increase Hepatic Fat Accumulation and Hepatic Antioxidant Protein Levels in APOE( − / − ) mice. J Proteome Res 6, 40414054.CrossRefGoogle ScholarPubMed
16de Roos, B, Duthie, SJ, Polley, AC, Mulholland, F, Bouwman, F, Heim, C, Rucklidge, G, Johnson, IT, Mariman, E, Daniel, H & Elliott, RM (2008) Proteomic methodological recommendations for studies involving human plasma, platelets and peripheral blood mononuclear cells. J Proteome Res, May 20 [Epub ahead of print].CrossRefGoogle ScholarPubMed
17de Roos, B, Rucklidge, G, Reid, M, Ross, K, Duncan, G, Navarro, MA, Arbones-Mainar, JM, Guzman-Garcia, MA, Osada, J, Browne, J, Loscher, CE & Roche, HM (2005) Divergent mechanisms of cis9, trans11-and trans10, cis12-conjugated linoleic acid affecting insulin resistance and inflammation in apolipoprotein E knockout mice: a proteomics approach. FASEB J 19, 17461748.CrossRefGoogle ScholarPubMed
18Shimizu, M, Tamamori-Adachi, M, Arai, H, Tabuchi, N, Tanaka, H & Sunamori, M (2002) Lipopolysaccharide pretreatment attenuates myocardial infarct size: a possible mechanism involving heat shock protein 70-inhibitory kappaBalpha complex and attenuation of nuclear factor kappaB. J Thorac Cardiovasc Surg 124, 933941.CrossRefGoogle Scholar
19Zhu, J, Quyyumi, AA, Wu, H, Csako, G, Rott, D, Zalles-Ganley, A, Ogunmakinwa, J, Halcox, J & Epstein, SE (2003) Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease. Arterioscler Thromb Vasc Biol 23, 10551059.CrossRefGoogle ScholarPubMed
20Dihal, AA, van der, WH, Hendriksen, PJ, Charif, H, Dekker, LJ, Ijsselstijn, L, de Boer, VC, Alink, GM, Burgers, PC, Rietjens, IM, Woutersen, RA & Stierum, RH (2008) Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics 8, 4561.CrossRefGoogle ScholarPubMed
21Tom, DH, Doring, F, Fuchs, D, Roth, HP & Daniel, H (2005) Transcriptome and proteome analysis identifies the pathways that increase hepatic lipid accumulation in zinc-deficient rats. J Nutr 135, 199205.Google Scholar
22Almeras, L, Eyles, D, Benech, P, Laffite, D, Villard, C, Patatian, A, Boucraut, J, Mackay-Sim, A, McGrath, J & Feron, F (2007) Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics 7, 769780.CrossRefGoogle ScholarPubMed
23Drew, JE, Padidar, S, Horgan, G, Duthie, GG, Russell, WR, Reid, M, Duncan, G & Rucklidge, GJ (2006) Salicylate modulates oxidative stress in the rat colon: a proteomic approach. Biochem Pharmacol 72, 204216.CrossRefGoogle Scholar
24Opii, WO, Joshi, G, Head, E, Milgram, NW, Muggenburg, BA, Klein, JB, Pierce, WM, Cotman, CW & Butterfield, DA (2008) Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging 29, 5170.CrossRefGoogle Scholar
25Astle, J, Ferguson, JT, German, JB, Harrigan, GG, Kelleher, NL, Kodadek, T, Parks, BA, Roth, MJ, Singletary, KW, Wenger, CD & Mahady, GB (2007) Characterization of proteomic and metabolomic responses to dietary factors and supplements. J Nutr 137, 27872793.CrossRefGoogle ScholarPubMed
26Coombes, KR, Morris, JS, Hu, J, Edmonson, SR & Baggerly, KA (2005) Serum proteomics profiling–a young technology begins to mature. Nat Biotechnol 23, 291292.CrossRefGoogle ScholarPubMed
27Gerszten, RE & Wang, TJ (2008) The search for new cardiovascular biomarkers. Nature 451, 949952.CrossRefGoogle ScholarPubMed
28de Roos, B, Geelen, A, Ross, K, Rucklidge, G, Reid, M, Duncan, G, Caslake, M, Horgan, G & Brouwer, IA (2008) Identification of potential serum biomarkers of inflammation and lipid modulation that are altered by fish oil supplementation in healthy volunteers. Proteomics 8, 19651974..CrossRefGoogle Scholar
29Fuchs, D, Piller, R, Linseisen, J, Daniel, H & Wenzel, U (2007) The human peripheral blood mononuclear cell proteome responds to a dietary flaxseed-intervention and proteins identified suggest a protective effect in atherosclerosis. Proteomics 7, 32783288.CrossRefGoogle ScholarPubMed
30Fuchs, D, Vafeiadou, K, Hall, WL, Daniel, H, Williams, CM, Schroot, JH & Wenzel, U (2007) Proteomic biomarkers of peripheral blood mononuclear cells obtained from postmenopausal women undergoing an intervention with soy isoflavones. Am J Clin Nutr 86, 13691375.CrossRefGoogle ScholarPubMed
31Vasan, RS (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113, 23352362.CrossRefGoogle ScholarPubMed
32Drake, TA & Ping, P (2007) Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Proteomics approaches to the systems biology of cardiovascular diseases. J Lipid Res 48, 18.CrossRefGoogle Scholar
33Issaq, HJ & Veenstra, TD (2007) The role of electrophoresis in disease biomarker discovery. Electrophoresis 28, 19801988.CrossRefGoogle ScholarPubMed
34Kussmann, M (2007) How to comprehensively analyse proteins and how this influences nutritional research. Clin Chem Lab Med 45, 288300.CrossRefGoogle ScholarPubMed
35Smolka, MB, Zhou, H, Purkayastha, S & Aebersold, R (2001) Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal Biochem 297, 2531.CrossRefGoogle ScholarPubMed
36Streckfus, CF, Mayorga-Wark, O, Arreola, D, Edwards, C, Bigler, L & Dubinsky, WP (2008) Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest 26, 159167.CrossRefGoogle ScholarPubMed
37Duncan, MW & Hunsucker, SW (2005) Proteomics as a tool for clinically relevant biomarker discovery and validation. Exp Biol Med (Maywood) 230, 808817.CrossRefGoogle ScholarPubMed
38Domon, B & Aebersold, R (2006) Mass spectrometry and protein analysis. Science 312, 212217.CrossRefGoogle ScholarPubMed
39Anderson, L & Hunter, CL (2006) Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 5, 573588.CrossRefGoogle ScholarPubMed
40Nielsen, UB & Geierstanger, BH (2004) Multiplexed sandwich assays in microarray format. J Immunol Methods 290, 107120.CrossRefGoogle ScholarPubMed
41Mariman, EC (2006) Nutrigenomics and nutrigenetics: the ‘omics’ revolution in nutritional science. Biotechnol Appl Biochem 44, 119128.CrossRefGoogle ScholarPubMed
42Cieniewski-Bernard, C, Acosta, A, Dubois, E, Lamblin, N, Beseme, O, Chwastyniak, M, Amouyel, P, Bauters, C & Pinet, F (2008) Proteomic analysis in cardiovascular diseases. Clin Exp Pharmacol Physiol 35, 362366.CrossRefGoogle ScholarPubMed
43Linke, T, Ross, AC & Harrison, EH (2004) Profiling of rat plasma by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, a novel tool for biomarker discovery in nutrition research. J Chromatogr A 1043, 6571.CrossRefGoogle ScholarPubMed
44Roelofsen, H, Balgobind, R & Vonk, RJ (2004) Proteomic analyzes of copper metabolism in an in vitro model of Wilson disease using surface enhanced laser desorption/ionization-time of flight-mass spectrometry. J Cell Biochem 93, 732740.CrossRefGoogle Scholar
45Reymond, MA & Schlegel, W (2007) Proteomics in cancer. Adv Clin Chem 44, 103142.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1 Reviews and research papers relating to proteomics, nutrition, diet and food published from 2000–2007.